We have developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases.
Our proprietary, synergistic toolkit allows us to precisely:
The field of RNA medicine holds limitless, untapped potential to rewrite the underlying basis of disease.
RNA medicines are currently limited by delivery to tissue targets and the absence of an integrated therapeutic platform
ReNAgade aims to overcome the limitations of RNA medicines by applying our comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale.
We have developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases.
Our proprietary, synergistic toolkit allows us to precisely:
For the first time, RNA medicines have the potential to treat any disease, anywhere in the body
POWERFUL POSITIONING
BEST-IN-CLASS TECH IN-HOUSE
FEARLESS TALENT
BLA=biologics license application; CTA=clinical trial application; IND=investigational new drug; NDA=new drug application.
“RNA without limits”, “Deliver-Code-Edit-Insert” are trademarks of ReNAgade Therapeutics, Inc.